[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369450-105":59,"doc-detail-369450-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","leveraging-a-disuldptosis-based-signature-to-characterize-heterogeneity-and-optimize-treatment-in-multiple-myeloma","Leveraging a disulﬁdptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma","","Disulﬁdptosis, an emerging programmed cell death driven by ROS accumulation and aberrant disulﬁde bond formation, is explored in relation to multiple myeloma (MM), a malignancy marked by disulﬁde-bond rich protein synthesis and chronic oxidative stress. Using non-negative matrix factorization and lasso on GEO, the study builds disulﬁdptosis-associated subtypes and a prognostic model, then integrates mutation mapping, interaction, enrichment, drug sensitivity and immune infiltration analyses. Clinical benefit is supported through a nomogram and in vitro validation of disulﬁdptosis-related gene expression, identifying subtype-specific prognosis, drug targets, and regulatory networks.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/leveraging-a-disuldptosis-based-signature-to-characterize-heterogeneity-and-optimize-treatment-in-multiple-myeloma/369450/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/leveraging-a-disuldptosis-based-signature-to-characterize-heterogeneity-and-optimize-treatment-in-multiple-myeloma/369450.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s primary goal regarding disulﬁdptosis and multiple myeloma?","Question",{"text":112,"@type":113},"To clarify the prognostic value of disulﬁdptosis in MM and to support identification of tumor heterogeneity and therapeutic targets through associated gene signatures and models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were disulﬁdptosis-associated subtypes and the prognostic model constructed?",{"text":117,"@type":113},"The study used non-negative matrix factorization and lasso on the GEO dataset, then built a prognostic model across subtypes and risk groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What key findings connect subtypes and risk groups to treatment response and immune features?",{"text":121,"@type":113},"A worse-prognosis subtype showed lower sensitivity to doxorubicin and lenalidomide, higher T-cell depletion, and resistance/non-response to immunotherapy, while risk-group scoring related to T-cell dysfunction, immunotherapy resistance, and altered signaling and metabolism.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369450,1790688105,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","TYPE Original Research PUBLISHED 16 April 2025  \nDOI 10.3389/fimmu.2025.1559317  \nOPEN ACCESS  \nEDITED BY  \nCristina Maccalli,  \nSidra Medicine, Qatar  \nREVIEWED BY  \nXiuli Wu,  \nJinan University, China Pan Chen,  \nCentral South University, China Geraldine O’Connor, University of Central Lancashire, United Kingdom  \n*CORRESPONDENCE  \nZhouxiang Jin  \n [wzjinzx@163.com](wzjinzx@163.com)[ ](wzjinzx@163.com)Songfu Jiang  \n[jiangsongfu@189.cn](jiangsongfu@189.cn)[ ](jiangsongfu@189.cn)Yongyong Ma  \n [mayy@wmu.edu.cn](mayy@wmu.edu.cn)  \nRECEIVED 12 January 2025  \nACCEPTED 26 March 2025  \nPUBLISHED 16 April 2025  \nCITATION  \nZhang B, Zheng D, Zhu S, Zhang X, Wang Q, Lin Z, Zheng Z, Zhou S, Chen Z, Zheng S, Lan E, Cui L, Ying H, Zhang Y, Lin X,  \nZhuang Q, Qian H, Hu X, Zhuang Y, Zhang Q, Jin Z, Jiang S and Ma Y (2025) Leveraging adisulﬁdptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.  \nFront. Immunol. 16:1559317 .  \ndoi: 10.3389/fimmu.2025.1559317  \nCOPYRIGHT  \n© 2025 Zhang, Zheng, Zhu, Zhang, Wang, Lin, Zheng, Zhou, Chen, Zheng, Lan, Cui, Ying, Zhang, Lin, Zhuang, Qian, Hu, Zhuang, Zhang, Jin, Jiang and Ma. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nLeveraging a disulﬁdptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma  \nBingxin Zhang 1, Dong Zheng 1, Shuxia Zhu 1, Xinyi Zhang 1, Quanqiang Wang 1, Zhili Lin 1, Ziwei Zheng 1, Shujuan Zhou 1, Zixing Chen 2, Sisi Zheng 1, Enqing Lan 2, Luning Cui 1, Hansen Ying 2, Yu Zhang 1, Xuanru Lin 1, Qiang Zhuang 1, Honglan Qian 1, Xudong Hu 1, Yan Zhuang 1, Qianying Zhang 1, Zhouxiang Jin 2*, Songfu Jiang 1* and Yongyong Ma 1,3,4*  \n1 Department of Hematology, The First Afﬁliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China, 2 Department of Hepatobiliary Surgery, The Second Afﬁliated Hospital and Yuying Children ’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China, 3 Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang, Wenzhou, Zhejiang, China, 4Zhejiang Engineering Research Center for Hospital Emergency and Process Digitization, Wenzhou, Zhejiang, China  \nBackground: Disulﬁdptosis is an emerging type of programmed cell death related to ROS accumulation and aberrant disulﬁde bond formation. Multiple myeloma (MM) is the second most prevalent hematologic malignancy characterized by a high synthesis rate of disulﬁde bond-rich proteins and chronic oxidative stress. However, the relationship between disulﬁdptosis and MM is still unclear.  \nMethods: Using the non-negative matrix factorization and lasso algorithm, we constructed the disulﬁdptosis-associated subtypes and the prognostic model on the GEO dataset. We further explored genetic mutation mapping, proteinprotein interactions, functional enrichment, drug sensitivity, drug prediction, and immune inﬁltration analysis among subtypes and risk subgroups. To improve the clinical beneﬁts, we combined risk scores and clinical metrics to build a nomogram. Finally, in vitro experiments examined the expression patterns of disulﬁdptosis-related genes (DRGs) in MM.  \nResults: By cluster analysis, we obtained three subtypes with C2 having a worse prognosis than C3 . Consistently, C2 exhibited signiﬁcantly lower sensitivity todoxorubicin and lenalidomide, as well as a higher propensity for T-cell depletion and a non-responsive state to immunotherapy. Similarly, in the subsequent prognostic model, the high-scoring group had a worse prognosis and a higher probability of T-cell dysfunction, im","cbCaiu6C4o6LgKxX","https://ap.wps.com/l/cbCaiu6C4o6LgKxX","pdf",19526553,24,"English","# Background\n# Methods\n## Computational subtype and prognostic modeling\n## Clinical and in vitro validation\n# Results\n## Subtype clustering and prognosis\n## Therapy response, T-cell dysfunction, and pathway differences\n## Drug target identification and regulatory networks\n# Conclusion\n# Keywords\n# 1 Introduction","[{\"question\":\"What is the study’s primary goal regarding disulﬁdptosis and multiple myeloma?\",\"answer\":\"To clarify the prognostic value of disulﬁdptosis in MM and to support identification of tumor heterogeneity and therapeutic targets through associated gene signatures and models.\"},{\"question\":\"How were disulﬁdptosis-associated subtypes and the prognostic model constructed?\",\"answer\":\"The study used non-negative matrix factorization and lasso on the GEO dataset, then built a prognostic model across subtypes and risk groups.\"},{\"question\":\"What key findings connect subtypes and risk groups to treatment response and immune features?\",\"answer\":\"A worse-prognosis subtype showed lower sensitivity to doxorubicin and lenalidomide, higher T-cell depletion, and resistance/non-response to immunotherapy, while risk-group scoring related to T-cell dysfunction, immunotherapy resistance, and altered signaling and metabolism.\"}]","Leveraging a disulﬁdptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma | PDF",1790182739,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebd3bb94b5e51e25bdc23165461e0fe0.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8b0e6d1473c57b40b31656a0e6d0111.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0bf891b9152b02d21e7ae07731dbdd5.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/123e68964bd2c8935852ce72d13e297d.webp",980,1385]